Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.48 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | TAOK3 | Q9H2K8 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6511811 | 1.00 | MTNR1A (0.48) | MTNR1AMTNR1BTAOK1HDAC8HDAC6 | |
| SCHEMBL6514673 | 0.83 | NPC1 (0.53) | MTNR1AMTNR1BTAOK1HDAC8HDAC6 | |
| SCHEMBL3394735 | 0.83 | NPC1 (0.53) | MTNR1AMTNR1BTAOK1HDAC8HDAC6 | |
| SCHEMBL3394652 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BTAOK1HDAC8HDAC6 | |
| SCHEMBL3394417 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BTAOK1HDAC8HDAC6 | |
| SCHEMBL6511815 | 0.78 | HTT (0.60) | HPGD | |
| SCHEMBL3392193 | 0.78 | HTT (0.60) | HPGD | |
| SCHEMBL3389865 | 0.76 | SMYD3 (0.58) | MTNR1AMTNR1BTAOK1TAOK3SMYD3 | |
| SCHEMBL3393775 | 0.76 | SMYD3 (0.58) | MTNR1AMTNR1BTAOK1TAOK3SMYD3 | |
| SCHEMBL9731843 | 0.75 | MTNR1A (0.67) | MTNR1AMTNR1BTAOK1TAOK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370530-B1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-6949556-B2 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1370530-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002064565-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | VEGFA, EDNRA, NR1H2 | MTNR1A 604/4885MTNR1B 448/4885TAOK1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.